G
G

GSK


خبر

British Business - Nov 23

Nov 23 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times A potential blockbuster blood cancer treatment Blenrep being developed by GSK Plc GSK.L is to be removed from the American market after a request from regulators. Cristiano Ronaldo has left Manchester United Plc MANU.N without receiving any compensation after the two parties agreed to rip up his contract.
B
G

UK Stocks-Factors to watch on Nov 22

Nov 22 - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday with futures FFIc1 up 0.25%. * GSK: GSK Plc GSK.L has initiated a process to withdraw the U.S. approval for its blood cancer drug Blenrep. * PETROFAC: Petrofac Ltd PFC.L appointed Tareq Kawash as the group's new chief executive officer. * BABCOCK: Babcock BAB.L posted a 5% rise in half-year operating profit and said it was focused on controlling the impact of inflation on its business as the cost of wages and materials inc
B
G
H
P
S
U

UK Stocks-Factors to watch on Nov 11

Nov 11 (Reuters) - Britain's FTSE 100 .FTSE index ticked higher on Friday and was up 0.03% as of 0909 GMT. * ECONOMY: Britain's economy shrank in the three months to September at the start of what is likely to be a lengthy recession, underscoring the challenge for finance minister Jeremy Hunt as he prepares to raise taxes and cut spending next week. * INFLATION: British finance minister Jeremy Hunt said on Friday the best way to help cash-strapped households hit by a cost of living squeeze was t
A
G
U

UK Stocks-Factors to watch on Nov 2

Nov 2 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.22% on Wednesday. * ASHTON MARTIN: British luxury carmaker Aston Martin AML.L warned that higher costs from global supply chain and logistical disruptions would hurt its margins, and lowered its wholesale delivery volume outlook for 2022. * GSK: GSK GSK.L beat analyst expectations for its third-quarter sales and profit, months after executing a rehaul of the business with the spin-off of its consumer
G
N
U

GSK lifts 2022 forecast again after stronger than expected quarter

By Natalie Grover Nov 2 (Reuters) - GSK GSK.L on Wednesday GSK GSK.L on Wednesday smashed analysts' estimates for third-quarter earnings, driven by higher sales of its blockbuster shingles vaccine, Shingrix. This quarter, Shingrix blew past expectations by generating sales of 760 million pounds ($872.86 million) compared to the GSK-compiled consensus of 685 million pounds.
B
G
P
S

GSK lifts 2022 forecast after stronger than expected quarter

Nov 2 (Reuters) - GSK GSK.L on Wednesday beat analyst expectations for its third-quarter sales and profit, months after executing a rehaul of the business with the spinoff of its consumer health unit. The British drugmaker, now solely focused on vaccines and medicines, reported adjusted profit of 46.9 pence on sales of about 7.83 billion pounds ($9 billion), compared with a company-compiled analyst consensus of 40.1 pence on sales of 7.32 billion pounds.
G

China bars GSK from bulk-buy drug programme for 18 months

By Natalie Grover BEIJING/LONDON, Oct 31 (Reuters) - China has blocked GSK GSK.L from participating in its bulk-buy drug procurement programme focused on off-patent medicines from Oct. 31 until April 29, 2024, over quality problems with a prostate drug, the British drugmaker said on Monday. First reported by CCTV state television, the ban was imposed by authorities after a batch of GSK's prostate treatment - known chemically as dutasteride and sold under the brand name Avodart - made by a Polish
G

Global firms urge governments to require mandatory disclosures on nature

* Over 330 businesses including Danone, Nestle back call * Signatories want large companies to assess, disclose impact * Unilever sustainability chief calls for 'decisive action' By Juliette Portala Oct 26 (Reuters) - Over 330 businesses on Wednesday urged world leaders to force large companies to assess and disclose their impact on nature by 2030, ahead of the COP15 global talks on biodiversity in December.
B
D
G
N
R
H

British Business - Oct 14

Oct 14 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - BT Group BT.L and other phone operators have been given another year to strip out Huawei technology from core 5G networks to avoid causing serious disruption to customers, the government said.
B
G
N

Nestle CEO: I'm not a 'mega deal' maker

ZURICH, Sept 29 (Reuters) - Food group Nestle NESN.S is in no hurry to acquire companies given rich valuations and will stick to its traditionally cautious approach to deals, its chief executive told a conference on Thursday. "I've done hundreds of deals in my life, the largest one ever was Starbucks at 7 billion so I'm not a 'mega deal' maker," Mark Schneider said in a discussion organised by Bernstein.
G
N
S

British Business - Sept 27

Sept 27 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Unilever plc ULVR.L is to start the search for a new chief executive officer after Alan Jope said that he intended to retire at the end of next year after five years in charge.
B
E
G
W

UK Stocks-Factors to watch on Sept 26

Sept 26 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.51% on Monday. * UNILEVER: Unilever ULVR.L CEO Alan Jope plans to retire at the end of 2023, the maker of Dove soap and Knorr stock cubes said on Monday, roughly two months after activist investor Nelson Peltz joined the board. * GSK: GSK GSK.L named luxury fashion brand Burberry's BRBY.L Julie Brown as its new chief financial officer to succeed Iain Mackay, at a time when the British drugmaker is s
B
B
G
R
U

UK Stocks-Factors to watch on Sept 26

Sept 26 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.28% on Monday. * GSK: British drugmaker GSK GSK.L has poached Burberry Group's BRBY.L finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday. * BARCLAYS: Barclays BARC.L was sued in a proposed U.S. class action in which shareholders claimed they were defrauded in connection with the British bank's sale of $17.6 billion more debt than regulators had allowed
B
B
G
R
U

British Business - Sept 23

Sept 23 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times The asset management business of HSBC Holdings Plc HSBA.L has set out plans to cut investments in thermal coal, months after one of its former top executives caused a furore with his comments about climate change.
G
H
R

UK Stocks-Factors to watch on Sept 20

Sept 20 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.57%. * HALEON: Haleon HLN.L said it had notified GSK GSK.L and Pfizer PFE.N that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac. * FULLER: Fuller, Smith & Turner FSTA.L warned that the global energy crisis would significantly raise its expected full-year costs for gas and electricity.
G
K
P
T
U

UK Stocks-Factors to watch on Aug 17

Aug 17 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening up 0.36%, with futures .FFIc1 up 0.15% on Wednesday. * BOOHOO: British online fashion retailer Boohoo BOOH.L said on Wednesday it had acquired a 7.1% stake in Revolution Beauty Group REVB.L , making it the fourth-largest shareholder of the beauty products maker. * PERSIMMON: Persimmon PSN.L forecast robust demand for new homes and reiterated its annual home completions outlook, dispelling fears of a slowdown in the sector, althoug
C
G
P
U

Financial Times - Aug 17

Aug 17 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Liz Truss and Rishi Sunak rule out second Scottish independence vote Link - UK launches legal proceedings against EU over access to Horizon programme Link - AstraZeneca sues former executive over move to rival GSK Link - Philips chief exits in wake of fallout from medical device recall Link Overview - Foreign secretary Liz Truss, f
A
G
P

UK first to approve Omicron COVID shot with Moderna nod

* UK's JCVI backs using bivalent shot in autumn booster campaign * Moderna sees Australia, Canada, EU approvals soon By Natalie Grover LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.
A
G
P
S

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

By Natalie Grover LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week.
G
P
S

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said in response to queries about sharp declines in Haleon shares.
G
S



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

ہم کوکیز کا استعمال آپکو ہماری ویب سائٹ پر بہتریں تجربہ دینے کیلیے کرتے ہیں۔ مزید پڑھیے یا اپنی کوکی سیٹنگ تبدیل کیجیے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔